Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical TechnologyPfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Italy leads the way on child genetic disease diagnosisNext: Asahi Kasei acquires German company Aicuris Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
